Journal: ACS Omega

Article Title: Modified Sanliangsan Improved Sjogren’s Syndrome Complicated with Interstitial Lung Disease by Suppressing Serum MUC1 Levels

doi: 10.1021/acsomega.4c01147

Figure Lengend Snippet: SP treatment suppresses hub SS-related MUC1 expression to improve SS-ILD. (A, B) Volcano plots display the DEGs in the salivary gland (A) and parotid (B) of patients with SS. The hub genes associated with SS are labeled by a black arrow. (C) Venn diagram displays the hub DEGs shared in the salivary gland, peripheral blood, and parotid of patients with SS. The DEGs from the salivary gland, peripheral blood, and parotid are represented by orange, gray, and blue circles, respectively. (D) Topological protein–protein interaction network of hub DEGs associated with SS. (E) Relative expression levels of APP and MUC1 in patients with SS-ILD vs healthy individuals. (F) Expression level of MUC1 in serum of patients with SS-ILD before and after SP and CK treatments. (G) ELISA of the serum protein levels of MUC1 in patients with SS-ILD before and after SP and CK treatments; “NS: no significance; * P < 0.05; ** P < 0.01”.

Article Snippet: The recombinant MUC1 protein was obtained by GST-tag protein purification kit (Beyotime Biotechnology, Shanghai, China), then collected, and dialyzed in PBS glycerol buffer.

Techniques: Expressing, Labeling, Enzyme-linked Immunosorbent Assay

Journal: ACS Omega

Article Title: Modified Sanliangsan Improved Sjogren’s Syndrome Complicated with Interstitial Lung Disease by Suppressing Serum MUC1 Levels

doi: 10.1021/acsomega.4c01147

Figure Lengend Snippet: SP therapy improves SS-LID by affecting the regulation network of MUC1 . (A) Scatter plot displays the pathway enrichment results of transcriptome profiles of the peripheral blood of patients with SS. The plot size and color represent the gene number and significance of each pathway. (B) Protein–protein interaction network showing the potential regulator of MUC1. (C) Expression of genes interacting with MUC1 in the serum of patients with SS-ILD after SP therapy.

Article Snippet: The recombinant MUC1 protein was obtained by GST-tag protein purification kit (Beyotime Biotechnology, Shanghai, China), then collected, and dialyzed in PBS glycerol buffer.

Techniques: Expressing

Journal: ACS Omega

Article Title: Modified Sanliangsan Improved Sjogren’s Syndrome Complicated with Interstitial Lung Disease by Suppressing Serum MUC1 Levels

doi: 10.1021/acsomega.4c01147

Figure Lengend Snippet: Network pharmacology analysis of SP in improving SS-ILD. (A) Category of metabolites from SP. (B) KEGG pathways analysis on targets of bioactive compounds of SP. (C) Integrated network of bioactive compounds and related proteins. (D) Molecular docking analysis detects the interaction between MUC1 protein and eugenol. (E) Isothermal titration calorimetry (ITC) enthalpograms of eugenol binding to MUC1. Titration data are presented as blue plots and fit as a black solid line. (F) RT-qPCR determines the effects of eugenol in affecting abnormal upregulation of genes involved in SS-ILD pathogenesis.

Article Snippet: The recombinant MUC1 protein was obtained by GST-tag protein purification kit (Beyotime Biotechnology, Shanghai, China), then collected, and dialyzed in PBS glycerol buffer.

Techniques: Isothermal Titration Calorimetry, Binding Assay, Titration, Quantitative RT-PCR